Rivaroxaban versus warfarin in nonvalvular atrial fibrillation [3]

New England Journal of Medicine

Volumn 365, Issue 24, 2011, Pages 2334-

  Rosenstein, Robert ^a   Parra, David ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RIVAROXABAN; WARFARIN; ANTICOAGULANT AGENT; MORPHOLINE DERIVATIVE; THIOPHENE DERIVATIVE; BLOOD CLOTTING FACTOR 10A INHIBITOR; BLOOD CLOTTING FACTOR 7A; THROMBIN INHIBITOR;

ANTICOAGULANT THERAPY; HAZARD RATIO; HEART ATRIUM FIBRILLATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; LETTER; OUTCOME ASSESSMENT; PHARMACOLOGICAL PARAMETERS; PRIORITY JOURNAL; TIME IN THE THERAPEUTIC RANGE; FEMALE; MALE; NOTE; ARTERY THROMBOSIS; BLEEDING; INJURY; PRESCRIPTION; THROMBOEMBOLISM;

ANTICOAGULANTS; ATRIAL FIBRILLATION; FEMALE; HUMANS; MALE; MORPHOLINES; THIOPHENES; WARFARIN;

EID: 84855168729     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: None     Document Type: Letter

References (2)

1. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51. [Erratum, N Engl J Med 2010;363:1877.]
2. FDA draft briefing document for the Cardiovascular and Renal Drugs Advisory Committee: Xarelto (rivaroxaban) tablets (http://www.fda.gov/downloads/ AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ CardiovascularandRenalDrugsAdvisoryCommittee/UCM270796.pdf).